AGMB · ISSUER CIK 2020932
AgomAb Therapeutics NV
Between Jul 31, 2026 and Oct 28, 2026, 3 AgomAb Therapeutics NV insiders reported $400K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Epstein David R (Director), with $220K.
↗3 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$400KInsider buying
$0.00Insider selling
+$400KNet open-market
Oct 22, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22, 202608:14 | Oct 21, 2026 | AGMB | Director | P · Buy | $8.88 | +10,000 | 25,000 | +67% | +$89K | -43.7% | -10.4% |
| Oct 9, 202608:01 | Oct 8, 2026 | AGMB | Director | P · Buy | $8.90 | +5,000 | 15,000 | +50% | +$45K | -43.6% | -10.6% |
| Oct 7, 202608:57 | Oct 6, 2026from Oct 5, 2026 | AGMB | Director | P · Buy | $8.64 | +10,000 | 10,000 | New | +$86K | -45.3% | -7.8% |
| Oct 7, 202608:47 | Oct 6, 2026 | AGMB | Chief Financial Officer | P · Buy | $8.59 | +10,000 | 10,000 | New | +$86K | -45.5% | -7.4% |
| Oct 7, 202608:06 | Oct 6, 2026from Oct 5, 2026 | AGMB | Chief Executive Officer, Director | P · Buy | $8.58 | +11,000 | 21,823 | +102% | +$94K | -45.6% | -7.2% |